Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can this watch spot a hidden heart problem?

NCT ID NCT04493749

Diagnosis Sponsor: Withings Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checks how well the Withings Move ECG watch can detect atrial fibrillation (an irregular heartbeat) compared to a standard 12-lead ECG. About 234 adults will wear the watch and get a standard ECG to see if the watch's automatic reading is accurate. The goal is to see if the watch can reliably flag AF, which could help people catch heart issues earlier.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 234 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2019

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

in and out patients from cardiology services

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * male or female who are 18 years or older * Subject who signed the written informed consent form Exclusion Criteria: * Vulnerable subject with regard to regulations * Pregnant, parturient or breastfeeding woman, * Subject who is deprived of liberty by judicial, medical or administrative decision, * Underage subject, * Legally protected subject, or subject who is unable to sign the written informed consent form, * Subject who is not beneficiary or not affiliated to a social security scheme, * Subject within several of the above categories, * Subject who refused to participate in the study, * Subject in physical incapacity to wear a wrist-worn watch * Subject with electrical stimulation by pacemaker

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation

Contacts and locations

Locations

  • Centre Cardiologique du Nord

    Saint-Denis, Île-de-France Region, 93200, France

  • Hopital Europeen Georges Pompidou

    Paris, Île-de-France Region, 75015, France

  • Institut Cœur Paris Centre Turin

    Paris, Île-de-France Region, 75008, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.